ARGENT BIOPHARMA LIMITED - Announcements

2.56%

8.0¢

Market Cap $5.774M

Healthcare Drug Manufacturers - Major

Argent BioPharma Ltd, formerly MGC Pharmaceuticals Ltd, is an Australia-based drug... Argent BioPharma Ltd, formerly MGC Pharmaceuticals Ltd, is an Australia-based drug discovery company. The Company is focused on developing and supplying accessible and ethically produced plant-derived medicines, combining in-house research with technologies. Its approach combines in-house research with technology, all discovering and producing treatments for unmet medical conditions. Its investigational medicinal (IMPs) products include CannEpil, CimetrA and CogniCann. CimetrA is a phyto medicine based on natural ingredients from Curcumin and Boswellia serrata, delivered in the nanoparticle delivery system, which is being developed for acute lung injury and acute respiratory distress syndrome (ARDS). CannEpil is a phyto medicine based on phytocannabinoid is being developed for the treatment of refractory epilepsy and cerebral palsy. CogniCann is a phyto medicine based on phytocannabinoids is in investigation stage as a treatment for the symptoms associated with dementia and Alzheimer.More

RCE'S BREAKTHROUGH

Recce Pharmaceuticals (ASX:RCE) accelerates commercialisation with positive Phase II results.

Announcements

Filter Results

All Price Sensitive Only

Filters [Clear]

Price Sensitive: Yes

RGT	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	15:03	717.33KB	Share
RGT	EU-GMP Cannabinoid API Supplied for Epilepsy in Slovenia	PRICE SENSITIVE	08/07/25	382.6KB	Share
RGT	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	30/04/25	571.2KB	Share
RGT	Strategic Collaboration Agreement for Malta Facility	PRICE SENSITIVE	09/04/25	385.61KB	Share
RGT	CannEpil Receives Approval for Prescription in Germany	PRICE SENSITIVE	03/04/25	435.04KB	Share
RGT	CimetrA Phase IIb Clinical Trial Results	PRICE SENSITIVE	17/03/25	499.66KB	Share
RGT	Strategic Manufacturing Partnership with ECCPharm Limited	PRICE SENSITIVE	05/03/25	379.22KB	Share
RGT	Half Year Accounts	PRICE SENSITIVE	28/02/25	926.44KB	Share
RGT	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	31/01/25	380.15KB	Share
RGT	Placing to Raise US$4,500,000	PRICE SENSITIVE	07/01/25	177.64KB	Share
RGT	Trading Halt	PRICE SENSITIVE	03/01/25	568.19KB	Share
RGT	ASX Listing Update	PRICE SENSITIVE	29/11/24	175.29KB	Share
RGT	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	31/10/24	376.42KB	Share
RGT	Placing to Raise A$200,000	PRICE SENSITIVE	24/10/24	190.2KB	Share
RGT	Preliminary Final Report	PRICE SENSITIVE	30/08/24	489.16KB	Share
RGT	Voluntary Delisting from ASX	PRICE SENSITIVE	15/08/24	255.33KB	Share
RGT	Trading Halt	PRICE SENSITIVE	13/08/24	564.56KB	Share
RGT	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	30/07/24	424.53KB	Share
RGT	Placing to Raise US$2,000,000	PRICE SENSITIVE	16/07/24	197.52KB	Share
RGT	Trading Halt	PRICE SENSITIVE	12/07/24	561.6KB	Share
RGT	Placing to Raise US$500,000	PRICE SENSITIVE	01/07/24	245.06KB	Share
RGT	Trading Halt	PRICE SENSITIVE	28/06/24	236.73KB	Share
RGT	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	30/04/24	448.09KB	Share
RGT	Half Year Accounts	PRICE SENSITIVE	29/02/24	1.01MB	Share
RGT	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	31/01/24	485.92KB	Share
RGT	Company Update & Capital Raising	PRICE SENSITIVE	22/12/23	252.55KB	Share
RGT	Retraction of Statement	PRICE SENSITIVE	21/12/23	198.15KB	Share
RGT	Pause in trading	PRICE SENSITIVE	21/12/23	116.81KB	Share
RGT	MGC Secures US$7.9 Million in Firm Commitments	PRICE SENSITIVE	01/11/23	270.27KB	Share
RGT	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	30/10/23	581.83KB	Share
RGT	Trading Halt	PRICE SENSITIVE	30/10/23	581KB	Share
RGT	Preliminary Final Report	PRICE SENSITIVE	31/08/23	642.18KB	Share
RGT	Share Purchase Plan Closed	PRICE SENSITIVE	30/08/23	227.06KB	Share
RGT	Pre-clinical Trial Results on CimetrA	PRICE SENSITIVE	14/08/23	279.17KB	Share
RGT	MGC Pharma Launches Share Purchase Plan	PRICE SENSITIVE	01/08/23	218.64KB	Share
RGT	MGC receives permission for first import of Psilocybin	PRICE SENSITIVE	31/07/23	256.18KB	Share
RGT	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	28/07/23	782.69KB	Share
RGT	Commitments Received for GBP 0.7m	PRICE SENSITIVE	14/07/23	482.3KB	Share
RGT	AMC Places Second Order of ArtemiC for US$1M	PRICE SENSITIVE	07/07/23	242.11KB	Share
RGT	Malta Production Facility Receives EU-GMP Approval	PRICE SENSITIVE	02/05/23	252.9KB	Share
RGT	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	28/04/23	598.45KB	Share
RGT	Fundraise closed raising up to a total of GBP 2.09m	PRICE SENSITIVE	13/04/23	352.17KB	Share
RGT	CannEpil now available by Named Patient Request in UK	PRICE SENSITIVE	11/04/23	282.24KB	Share
RGT	Funding Commitments Received for GBP 1.8m	PRICE SENSITIVE	11/04/23	580.07KB	Share
RGT	Trading Halt	PRICE SENSITIVE	11/04/23	583.48KB	Share
RGT	MGC Receive Permission for Psilocybin Research & Development	PRICE SENSITIVE	03/04/23	243.11KB	Share
RGT	ArtemiC Listed as OTC Drug in USA, AMC Places US$2m Order	PRICE SENSITIVE	21/03/23	281.01KB	Share
RGT	Completion of CimetrA Mechanism of Action study	PRICE SENSITIVE	07/03/23	324.77KB	Share
RGT	Half Year Accounts	PRICE SENSITIVE	28/02/23	762.24KB	Share
RGT	Provision of US$600,000 Funding and change of CFO	PRICE SENSITIVE	03/02/23	203.44KB	Share
RGT	Refinancing and Extension to Convertible Security Agreements	PRICE SENSITIVE	02/02/23	215.36KB	Share
RGT	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	30/01/23	1.55MB	Share
RGT	Results of CimetrA bioanalytics pre-clinal trial	PRICE SENSITIVE	10/01/23	349.88KB	Share
RGT	Internal Costs Review Completed and Board Change	PRICE SENSITIVE	03/01/23	249.35KB	Share
RGT	$800,000 of funding received through Mercer Facility	PRICE SENSITIVE	23/12/22	235.46KB	Share
RGT	Completion of CimetrA Efficacy Pre-clinical Trial	PRICE SENSITIVE	07/12/22	224.62KB	Share
RGT	US$1,000,000 ArtemiC order delivered to US partner, AMC	PRICE SENSITIVE	05/12/22	269.38KB	Share
RGT	Publication of Peer Reviewed Glioblastoma Research	PRICE SENSITIVE	02/12/22	363.02KB	Share
RGT	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	31/10/22	397.63KB	Share
RGT	Long COVID study Results	PRICE SENSITIVE	25/10/22	496.19KB	Share
RGT	Trading Halt	PRICE SENSITIVE	24/10/22	978.04KB	Share
RGT	Pause in Trading	PRICE SENSITIVE	24/10/22	116.1KB	Share
RGT	Operations Update	PRICE SENSITIVE	20/10/22	237.39KB	Share
RGT	Appointment of UK Corporate Advisor and Company Update	PRICE SENSITIVE	04/10/22	906.45KB	Share
RGT	TGA advertising Infringement Notice	PRICE SENSITIVE	28/09/22	169.23KB	Share
RGT	US$550,000 Convertible Note Facility Funding	PRICE SENSITIVE	23/09/22	216.97KB	Share
RGT	Interim Results - CimetrA Dosing Finding Study	PRICE SENSITIVE	21/09/22	280.99KB	Share
RGT	Preliminary Final Report	PRICE SENSITIVE	01/09/22	514.78KB	Share
RGT	US$750,000 Convertible Note Facility Funding	PRICE SENSITIVE	25/08/22	198.01KB	Share
RGT	AMC Holdings Inc places US$1 million ArtemiC order	PRICE SENSITIVE	17/08/22	260.59KB	Share
RGT	Study Results - Effects of CannEpil on driving performance	PRICE SENSITIVE	15/08/22	915.06KB	Share
RGT	US$1.2M Tranche 1 Funding Recevied from Mercer	PRICE SENSITIVE	03/08/22	206.13KB	Share
RGT	US$10M Financing Agreement signed with US Financier/Investor	PRICE SENSITIVE	29/07/22	247.08KB	Share
RGT	Strategic Acquisition of 40% interest in ZAM Software Ltd	PRICE SENSITIVE	28/07/22	241.87KB	Share
RGT	Amended June Quarterly Reports (amended App. 4C)	PRICE SENSITIVE	25/07/22	333KB	Share
RGT	June Quarter Activities and Cash Flow Report	PRICE SENSITIVE	25/07/22	332.89KB	Share
RGT	Long COVID Study Results for ArtemiC Support	PRICE SENSITIVE	14/07/22	391.7KB	Share
RGT	Approvals received for South African CimetrA Clinical Trial	PRICE SENSITIVE	08/07/22	249.52KB	Share
RGT	CimetrA anti-inflammatory pre-clinical study results	PRICE SENSITIVE	27/06/22	1.11MB	Share
RGT	Glioblastoma pre-clinical trial results	PRICE SENSITIVE	16/06/22	1.14MB	Share
RGT	Cognicann Clinical Trial Results	PRICE SENSITIVE	06/06/22	348.51KB	Share
RGT	Response to ASX Aware Query	PRICE SENSITIVE	18/05/22	1.18MB	Share
RGT	Patent Granted for CannEpiL SNEDDS	PRICE SENSITIVE	10/05/22	283.84KB	Share
RGT	March 2022 Quarterly Activity and Cash Flow Reports	PRICE SENSITIVE	29/04/22	1.16MB	Share
RGT	Patent Granted for CimetrA	PRICE SENSITIVE	21/04/22	1012.55KB	Share
RGT	Sciensus Rare EU & UK Sales and Distribution Agreement	PRICE SENSITIVE	05/04/22	927.81KB	Share
RGT	Half Yearly Report and Accounts	PRICE SENSITIVE	01/03/22	901.72KB	Share
RGT	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	31/01/22	1.8MB	Share
RGT	Response to ASX Query	PRICE SENSITIVE	12/01/22	1.37MB	Share
RGT	ArtemiC receives Indian importation and sales approval	PRICE SENSITIVE	07/01/22	959.91KB	Share
RGT	ArtemiC Long COVID Syndrome Clinical Study Commenced	PRICE SENSITIVE	21/12/21	1.09MB	Share
RGT	UK Capital Raising Completed	PRICE SENSITIVE	01/12/21	259.96KB	Share
RGT	Trading Halt	PRICE SENSITIVE	30/11/21	1.16MB	Share
RGT	Production Completed of A$1M ArtemiC Order from SPC	PRICE SENSITIVE	25/11/21	859.79KB	Share
RGT	US Supply and Distribution Agreement Update	PRICE SENSITIVE	23/11/21	934.88KB	Share
RGT	MALTA CIMETRA PRODUCTION FACILITY UPDATE	PRICE SENSITIVE	03/11/21	245.97KB	Share
RGT	CIMETRA DOSE FINDING STUDY APPROVAL	PRICE SENSITIVE	02/11/21	281.87KB	Share
RGT	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	26/10/21	1.93MB	Share
RGT	Response to ASX Query Letter	PRICE SENSITIVE	15/10/21	712.18KB	Share
RGT	AMC INC. PLACES US$3M CIMETRA PURCHASE ORDER	PRICE SENSITIVE	07/10/21	952.83KB	Share

RGT Quarterly Activities/Appendix 4C Cash Flow Report
15:03	PRICE SENSITIVE	717.33KB	Share
RGT EU-GMP Cannabinoid API Supplied for Epilepsy in Slovenia
08/07/25	PRICE SENSITIVE	382.6KB	Share
RGT Quarterly Activities/Appendix 4C Cash Flow Report
30/04/25	PRICE SENSITIVE	571.2KB	Share
RGT Strategic Collaboration Agreement for Malta Facility
09/04/25	PRICE SENSITIVE	385.61KB	Share
RGT CannEpil Receives Approval for Prescription in Germany
03/04/25	PRICE SENSITIVE	435.04KB	Share
RGT CimetrA Phase IIb Clinical Trial Results
17/03/25	PRICE SENSITIVE	499.66KB	Share
RGT Strategic Manufacturing Partnership with ECCPharm Limited
05/03/25	PRICE SENSITIVE	379.22KB	Share
RGT Half Year Accounts
28/02/25	PRICE SENSITIVE	926.44KB	Share
RGT Quarterly Activities/Appendix 4C Cash Flow Report
31/01/25	PRICE SENSITIVE	380.15KB	Share
RGT Placing to Raise US$4,500,000
07/01/25	PRICE SENSITIVE	177.64KB	Share
RGT Trading Halt
03/01/25	PRICE SENSITIVE	568.19KB	Share
RGT ASX Listing Update
29/11/24	PRICE SENSITIVE	175.29KB	Share
RGT Quarterly Activities/Appendix 4C Cash Flow Report
31/10/24	PRICE SENSITIVE	376.42KB	Share
RGT Placing to Raise A$200,000
24/10/24	PRICE SENSITIVE	190.2KB	Share
RGT Preliminary Final Report
30/08/24	PRICE SENSITIVE	489.16KB	Share
RGT Voluntary Delisting from ASX
15/08/24	PRICE SENSITIVE	255.33KB	Share
RGT Trading Halt
13/08/24	PRICE SENSITIVE	564.56KB	Share
RGT Quarterly Activities/Appendix 4C Cash Flow Report
30/07/24	PRICE SENSITIVE	424.53KB	Share
RGT Placing to Raise US$2,000,000
16/07/24	PRICE SENSITIVE	197.52KB	Share
RGT Trading Halt
12/07/24	PRICE SENSITIVE	561.6KB	Share
RGT Placing to Raise US$500,000
01/07/24	PRICE SENSITIVE	245.06KB	Share
RGT Trading Halt
28/06/24	PRICE SENSITIVE	236.73KB	Share
RGT Quarterly Activities/Appendix 4C Cash Flow Report
30/04/24	PRICE SENSITIVE	448.09KB	Share
RGT Half Year Accounts
29/02/24	PRICE SENSITIVE	1.01MB	Share
RGT Quarterly Activities/Appendix 4C Cash Flow Report
31/01/24	PRICE SENSITIVE	485.92KB	Share
RGT Company Update & Capital Raising
22/12/23	PRICE SENSITIVE	252.55KB	Share
RGT Retraction of Statement
21/12/23	PRICE SENSITIVE	198.15KB	Share
RGT Pause in trading
21/12/23	PRICE SENSITIVE	116.81KB	Share
RGT MGC Secures US$7.9 Million in Firm Commitments
01/11/23	PRICE SENSITIVE	270.27KB	Share
RGT Quarterly Activities/Appendix 4C Cash Flow Report
30/10/23	PRICE SENSITIVE	581.83KB	Share
RGT Trading Halt
30/10/23	PRICE SENSITIVE	581KB	Share
RGT Preliminary Final Report
31/08/23	PRICE SENSITIVE	642.18KB	Share
RGT Share Purchase Plan Closed
30/08/23	PRICE SENSITIVE	227.06KB	Share
RGT Pre-clinical Trial Results on CimetrA
14/08/23	PRICE SENSITIVE	279.17KB	Share
RGT MGC Pharma Launches Share Purchase Plan
01/08/23	PRICE SENSITIVE	218.64KB	Share
RGT MGC receives permission for first import of Psilocybin
31/07/23	PRICE SENSITIVE	256.18KB	Share
RGT Quarterly Activities/Appendix 4C Cash Flow Report
28/07/23	PRICE SENSITIVE	782.69KB	Share
RGT Commitments Received for GBP 0.7m
14/07/23	PRICE SENSITIVE	482.3KB	Share
RGT AMC Places Second Order of ArtemiC for US$1M
07/07/23	PRICE SENSITIVE	242.11KB	Share
RGT Malta Production Facility Receives EU-GMP Approval
02/05/23	PRICE SENSITIVE	252.9KB	Share
RGT Quarterly Activities/Appendix 4C Cash Flow Report
28/04/23	PRICE SENSITIVE	598.45KB	Share
RGT Fundraise closed raising up to a total of GBP 2.09m
13/04/23	PRICE SENSITIVE	352.17KB	Share
RGT CannEpil now available by Named Patient Request in UK
11/04/23	PRICE SENSITIVE	282.24KB	Share
RGT Funding Commitments Received for GBP 1.8m
11/04/23	PRICE SENSITIVE	580.07KB	Share
RGT Trading Halt
11/04/23	PRICE SENSITIVE	583.48KB	Share
RGT MGC Receive Permission for Psilocybin Research & Development
03/04/23	PRICE SENSITIVE	243.11KB	Share
RGT ArtemiC Listed as OTC Drug in USA, AMC Places US$2m Order
21/03/23	PRICE SENSITIVE	281.01KB	Share
RGT Completion of CimetrA Mechanism of Action study
07/03/23	PRICE SENSITIVE	324.77KB	Share
RGT Half Year Accounts
28/02/23	PRICE SENSITIVE	762.24KB	Share
RGT Provision of US$600,000 Funding and change of CFO
03/02/23	PRICE SENSITIVE	203.44KB	Share
RGT Refinancing and Extension to Convertible Security Agreements
02/02/23	PRICE SENSITIVE	215.36KB	Share
RGT Quarterly Activities/Appendix 4C Cash Flow Report
30/01/23	PRICE SENSITIVE	1.55MB	Share
RGT Results of CimetrA bioanalytics pre-clinal trial
10/01/23	PRICE SENSITIVE	349.88KB	Share
RGT Internal Costs Review Completed and Board Change
03/01/23	PRICE SENSITIVE	249.35KB	Share
RGT $800,000 of funding received through Mercer Facility
23/12/22	PRICE SENSITIVE	235.46KB	Share
RGT Completion of CimetrA Efficacy Pre-clinical Trial
07/12/22	PRICE SENSITIVE	224.62KB	Share
RGT US$1,000,000 ArtemiC order delivered to US partner, AMC
05/12/22	PRICE SENSITIVE	269.38KB	Share
RGT Publication of Peer Reviewed Glioblastoma Research
02/12/22	PRICE SENSITIVE	363.02KB	Share
RGT Quarterly Activities/Appendix 4C Cash Flow Report
31/10/22	PRICE SENSITIVE	397.63KB	Share
RGT Long COVID study Results
25/10/22	PRICE SENSITIVE	496.19KB	Share
RGT Trading Halt
24/10/22	PRICE SENSITIVE	978.04KB	Share
RGT Pause in Trading
24/10/22	PRICE SENSITIVE	116.1KB	Share
RGT Operations Update
20/10/22	PRICE SENSITIVE	237.39KB	Share
RGT Appointment of UK Corporate Advisor and Company Update
04/10/22	PRICE SENSITIVE	906.45KB	Share
RGT TGA advertising Infringement Notice
28/09/22	PRICE SENSITIVE	169.23KB	Share
RGT US$550,000 Convertible Note Facility Funding
23/09/22	PRICE SENSITIVE	216.97KB	Share
RGT Interim Results - CimetrA Dosing Finding Study
21/09/22	PRICE SENSITIVE	280.99KB	Share
RGT Preliminary Final Report
01/09/22	PRICE SENSITIVE	514.78KB	Share
RGT US$750,000 Convertible Note Facility Funding
25/08/22	PRICE SENSITIVE	198.01KB	Share
RGT AMC Holdings Inc places US$1 million ArtemiC order
17/08/22	PRICE SENSITIVE	260.59KB	Share
RGT Study Results - Effects of CannEpil on driving performance
15/08/22	PRICE SENSITIVE	915.06KB	Share
RGT US$1.2M Tranche 1 Funding Recevied from Mercer
03/08/22	PRICE SENSITIVE	206.13KB	Share
RGT US$10M Financing Agreement signed with US Financier/Investor
29/07/22	PRICE SENSITIVE	247.08KB	Share
RGT Strategic Acquisition of 40% interest in ZAM Software Ltd
28/07/22	PRICE SENSITIVE	241.87KB	Share
RGT Amended June Quarterly Reports (amended App. 4C)
25/07/22	PRICE SENSITIVE	333KB	Share
RGT June Quarter Activities and Cash Flow Report
25/07/22	PRICE SENSITIVE	332.89KB	Share
RGT Long COVID Study Results for ArtemiC Support
14/07/22	PRICE SENSITIVE	391.7KB	Share
RGT Approvals received for South African CimetrA Clinical Trial
08/07/22	PRICE SENSITIVE	249.52KB	Share
RGT CimetrA anti-inflammatory pre-clinical study results
27/06/22	PRICE SENSITIVE	1.11MB	Share
RGT Glioblastoma pre-clinical trial results
16/06/22	PRICE SENSITIVE	1.14MB	Share
RGT Cognicann Clinical Trial Results
06/06/22	PRICE SENSITIVE	348.51KB	Share
RGT Response to ASX Aware Query
18/05/22	PRICE SENSITIVE	1.18MB	Share
RGT Patent Granted for CannEpiL SNEDDS
10/05/22	PRICE SENSITIVE	283.84KB	Share
RGT March 2022 Quarterly Activity and Cash Flow Reports
29/04/22	PRICE SENSITIVE	1.16MB	Share
RGT Patent Granted for CimetrA
21/04/22	PRICE SENSITIVE	1012.55KB	Share
RGT Sciensus Rare EU & UK Sales and Distribution Agreement
05/04/22	PRICE SENSITIVE	927.81KB	Share
RGT Half Yearly Report and Accounts
01/03/22	PRICE SENSITIVE	901.72KB	Share
RGT Quarterly Activities/Appendix 4C Cash Flow Report
31/01/22	PRICE SENSITIVE	1.8MB	Share
RGT Response to ASX Query
12/01/22	PRICE SENSITIVE	1.37MB	Share
RGT ArtemiC receives Indian importation and sales approval
07/01/22	PRICE SENSITIVE	959.91KB	Share
RGT ArtemiC Long COVID Syndrome Clinical Study Commenced
21/12/21	PRICE SENSITIVE	1.09MB	Share
RGT UK Capital Raising Completed
01/12/21	PRICE SENSITIVE	259.96KB	Share
RGT Trading Halt
30/11/21	PRICE SENSITIVE	1.16MB	Share
RGT Production Completed of A$1M ArtemiC Order from SPC
25/11/21	PRICE SENSITIVE	859.79KB	Share
RGT US Supply and Distribution Agreement Update
23/11/21	PRICE SENSITIVE	934.88KB	Share
RGT MALTA CIMETRA PRODUCTION FACILITY UPDATE
03/11/21	PRICE SENSITIVE	245.97KB	Share
RGT CIMETRA DOSE FINDING STUDY APPROVAL
02/11/21	PRICE SENSITIVE	281.87KB	Share
RGT Quarterly Activities/Appendix 4C Cash Flow Report
26/10/21	PRICE SENSITIVE	1.93MB	Share
RGT Response to ASX Query Letter
15/10/21	PRICE SENSITIVE	712.18KB	Share
RGT AMC INC. PLACES US$3M CIMETRA PURCHASE ORDER
07/10/21	PRICE SENSITIVE	952.83KB	Share

REFRESH

1 2 3 4

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last 8.0¢		Change 0.002(2.56%)		Mkt cap ! $5.774M

Open	High	Low	Value	Volume
8.0¢	8.0¢	8.0¢	$805	10.06K

Buyers (Bids)

No.	Vol.	Price($)
1	939	8.0¢

Sellers (Offers)

Price($)	Vol.	No.
9.0¢	3666	1

View Market Depth

No.	Vol.	Price($)
1	939	0.080
1	954	0.078
1	8000	0.075
2	57900	0.074
5	175212	0.073

Price($)	Vol.	No.
0.090	3666	1
0.095	74	1
0.120	8340	1
0.160	5046	1
0.170	5450	1

Last trade - 10.10am 31/07/2025 (20 minute delay)

RGT (ASX) Chart

ARGENT BIOPHARMA LIMITED - Announcements

Announcements

Buyers (Bids)

Sellers (Offers)

Infini Resources appoints Rohan Bone as CEO ahead of Phase 2 campaign

Resolution Minerals appoints industry experts to fast-track US growth strategy

Top Stories